Pharmacy Drugs
Recent Posts
- Beta Blockers May Increase Risk For Surgical Anemia Complications
- Alimera Announces Positive Results From The Two Phase 3 FAME(TM) Trials Of Iluvien(R) In Patients With Diabetic Macular Edema
- Lytix Biopharma AS Announces Regulatory Approval By Norwegian And Swedish Authorities To Commence Phase I Clinical Trial Of OncoporeTM In Cancer
- NPA Responds To Quality Accounts Consultation, UK
- Novelos Therapeutics’ (NVLT.OB) CEO Is Eyeing “Revolutionary” Phase III Study Results
Random Posts
- Ligand Initiates Clinical Trial With The Selective Androgen Receptor Modulator LGD-4033, A Potential Treatment Of Muscle And Bone Disorders
- PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study Of PEAK PlasmaBlade(TM) For Gynecologic Surgery
- It Is Better To Be In The Hospital For Treating Bulimia Nervosa?
- Study Aims To Induce Recovery From Ankylosing Spondylitis
- IAVI Statement On Results Of Phase III ALVAC-AIDSVAX Trial In Thailand
- New Device Gauges Breast Tumor Margins During Surgery
- Experts To Assess Impacts And Policy Barriers To Improving Proper Medication Adherence
- FDA Approves New Antiplatelet for Angioplasty Patients
- FDA Likely to Approve H1N1 Vaccine In Advance of Data
- SPIRIT IV Results Reaffirm Strong Performance Of Boston Scientific PROMUS(R) And TAXUS(R) Express(R) Stents
Potentially Dangerous Drug Interactions Missed By Prescribers
Posted by: admin in Pharmacy Drugs on August 29th, 2009
Research led by The University of Arizona College of Pharmacy has found that medication prescribers correctly identified fewer than half of drug pairs with potentially dangerous drug-drug interactions.
These findings raise concern because of the high number of drugs Americans take: an average of 2.3 medications is prescribed during each physician office visit.
A synopsis of the research was published in May Research Activities, a digest of research findings intended to contribute to the national policymaking process.
The researchers, led by Daniel Malone, PhD, professor at the UA College of Pharmacy, mailed a questionnaire to 12,500 U.S. prescribers who were selected based on a history of prescribing drugs associated with known potential for drug-drug interaction. Prescribers were primarily physicians, physicians’ assistants and nurse practitioners.
Recipients were asked to classify 14 drug pairs as “contraindicated,” “may be used together but with monitoring” or “no interaction.” Respondents could also state that they were “not sure.”
For the drug pairs, one commonly prescribed medication was matched with another commonly prescribed medication.
The 950 respondents classified 42.7 percent of all drug combinations correctly.
Of the 14 drug pairs presented, four of them were contraindicated, meaning they should not be used together. A majority of prescribers correctly identified only one of the four pairs as contraindicated.
Moreover, for half of the 14 drug pairs, more than one-third of the respondents answered that they were “not sure,” and two of these drug pairs were contraindicated.
“The study found a very low rate of recognition of these particular interactions,” says Malone, “and some of these interactions are very common.”
Use of several of the contraindicated drug pairs could be dangerous. For example, taking sildenafil (Viagra®) and nitrates, such as isosorbide mononitrate, can be life-threatening.
According to Malone, the research indicates that health professional programs are not doing enough to teach students about potential drug-drug interactions. Consequently, patients should be sure to tell their pharmacist of all the medications they are taking.
Source:
Karin Lorentzen
University of Arizona, College of Pharmacy
View drug information on Viagra.